To better determine whether there is a difference in LEAP-2 expression levels between MAFLD and a specific type of other liver diseases, we conducted a supplementary experiment that included patients who visited West China Hospital of Sichuan University from June 2023 to February 2024, consisting of 14 MAFLD, 13 AIH, 12 ALD, and 11 viral hepatitis. Here, LEAP2 is linked to liver disorder.